Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.
This report aims to provide a comprehensive presentation of the global market for Gene Therapy for Age-related Macular Degeneration, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy for Age-related Macular Degeneration. This report contains market size and forecasts of Gene Therapy for Age-related Macular Degeneration in global, including the following market information:
Global Gene Therapy for Age-related Macular Degeneration Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Gene Therapy for Age-related Macular Degeneration market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the market's growth.
We surveyed the Gene Therapy for Age-related Macular Degeneration companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Gene Therapy for Age-related Macular Degeneration Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Gene Therapy for Age-related Macular Degeneration Market Segment Percentages, by Type, 2022 (%)
Subretinal
Intravitreal
Global Gene Therapy for Age-related Macular Degeneration Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Gene Therapy for Age-related Macular Degeneration Market Segment Percentages, by Application, 2022 (%)
Monotherapy
Combination Therapy
Global Gene Therapy for Age-related Macular Degeneration Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Gene Therapy for Age-related Macular Degeneration Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Gene Therapy for Age-related Macular Degeneration revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Gene Therapy for Age-related Macular Degeneration revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
RetroSense Therapeutics
REGENXBIO
AGTC
Outline of Major Chapters:
Chapter 1: Introduces the definition of Gene Therapy for Age-related Macular Degeneration, market overview.
Chapter 2: Global Gene Therapy for Age-related Macular Degeneration market size in revenue.
Chapter 3: Detailed analysis of Gene Therapy for Age-related Macular Degeneration company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gene Therapy for Age-related Macular Degeneration in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Gene Therapy for Age-related Macular Degeneration Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Gene Therapy for Age-related Macular Degeneration Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Gene Therapy for Age-related Macular Degeneration Overall Market Size
2.1 Global Gene Therapy for Age-related Macular Degeneration Market Size: 2022 VS 2029
2.2 Global Gene Therapy for Age-related Macular Degeneration Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Gene Therapy for Age-related Macular Degeneration Players in Global Market
3.2 Top Global Gene Therapy for Age-related Macular Degeneration Companies Ranked by Revenue
3.3 Global Gene Therapy for Age-related Macular Degeneration Revenue by Companies
3.4 Top 3 and Top 5 Gene Therapy for Age-related Macular Degeneration Companies in Global Market, by Revenue in 2022
3.5 Global Companies Gene Therapy for Age-related Macular Degeneration Product Type
3.6 Tier 1, Tier 2 and Tier 3 Gene Therapy for Age-related Macular Degeneration Players in Global Market
3.6.1 List of Global Tier 1 Gene Therapy for Age-related Macular Degeneration Companies
3.6.2 List of Global Tier 2 and Tier 3 Gene Therapy for Age-related Macular Degeneration Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Gene Therapy for Age-related Macular Degeneration Market Size Markets, 2022 & 2029
4.1.2 Subretinal
4.1.3 Intravitreal
4.2 By Type - Global Gene Therapy for Age-related Macular Degeneration Revenue & Forecasts
4.2.1 By Type - Global Gene Therapy for Age-related Macular Degeneration Revenue, 2018-2023
4.2.2 By Type - Global Gene Therapy for Age-related Macular Degeneration Revenue, 2024-2029
4.2.3 By Type - Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Gene Therapy for Age-related Macular Degeneration Market Size, 2022 & 2029
5.1.2 Monotherapy
5.1.3 Combination Therapy
5.2 By Application - Global Gene Therapy for Age-related Macular Degeneration Revenue & Forecasts
5.2.1 By Application - Global Gene Therapy for Age-related Macular Degeneration Revenue, 2018-2023
5.2.2 By Application - Global Gene Therapy for Age-related Macular Degeneration Revenue, 2024-2029
5.2.3 By Application - Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Gene Therapy for Age-related Macular Degeneration Market Size, 2022 & 2029
6.2 By Region - Global Gene Therapy for Age-related Macular Degeneration Revenue & Forecasts
6.2.1 By Region - Global Gene Therapy for Age-related Macular Degeneration Revenue, 2018-2023
6.2.2 By Region - Global Gene Therapy for Age-related Macular Degeneration Revenue, 2024-2029
6.2.3 By Region - Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Gene Therapy for Age-related Macular Degeneration Revenue, 2018-2029
6.3.2 US Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.3.3 Canada Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.3.4 Mexico Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Gene Therapy for Age-related Macular Degeneration Revenue, 2018-2029
6.4.2 Germany Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.4.3 France Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.4.4 U.K. Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.4.5 Italy Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.4.6 Russia Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.4.7 Nordic Countries Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.4.8 Benelux Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Gene Therapy for Age-related Macular Degeneration Revenue, 2018-2029
6.5.2 China Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.5.3 Japan Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.5.4 South Korea Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.5.5 Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.5.6 India Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Gene Therapy for Age-related Macular Degeneration Revenue, 2018-2029
6.6.2 Brazil Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.6.3 Argentina Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Gene Therapy for Age-related Macular Degeneration Revenue, 2018-2029
6.7.2 Turkey Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.7.3 Israel Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.7.4 Saudi Arabia Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
6.7.5 UAE Gene Therapy for Age-related Macular Degeneration Market Size, 2018-2029
7 Gene Therapy for Age-related Macular Degeneration Companies Profiles
7.1 RetroSense Therapeutics
7.1.1 RetroSense Therapeutics Company Summary
7.1.2 RetroSense Therapeutics Business Overview
7.1.3 RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Major Product Offerings
7.1.4 RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Revenue in Global Market (2018-2023)
7.1.5 RetroSense Therapeutics Key News & Latest Developments
7.2 REGENXBIO
7.2.1 REGENXBIO Company Summary
7.2.2 REGENXBIO Business Overview
7.2.3 REGENXBIO Gene Therapy for Age-related Macular Degeneration Major Product Offerings
7.2.4 REGENXBIO Gene Therapy for Age-related Macular Degeneration Revenue in Global Market (2018-2023)
7.2.5 REGENXBIO Key News & Latest Developments
7.3 AGTC
7.3.1 AGTC Company Summary
7.3.2 AGTC Business Overview
7.3.3 AGTC Gene Therapy for Age-related Macular Degeneration Major Product Offerings
7.3.4 AGTC Gene Therapy for Age-related Macular Degeneration Revenue in Global Market (2018-2023)
7.3.5 AGTC Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Gene Therapy for Age-related Macular Degeneration Market Opportunities & Trends in Global Market
Table 2. Gene Therapy for Age-related Macular Degeneration Market Drivers in Global Market
Table 3. Gene Therapy for Age-related Macular Degeneration Market Restraints in Global Market
Table 4. Key Players of Gene Therapy for Age-related Macular Degeneration in Global Market
Table 5. Top Gene Therapy for Age-related Macular Degeneration Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Gene Therapy for Age-related Macular Degeneration Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Gene Therapy for Age-related Macular Degeneration Revenue Share by Companies, 2018-2023
Table 8. Global Companies Gene Therapy for Age-related Macular Degeneration Product Type
Table 9. List of Global Tier 1 Gene Therapy for Age-related Macular Degeneration Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Gene Therapy for Age-related Macular Degeneration Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Gene Therapy for Age-related Macular Degeneration Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Gene Therapy for Age-related Macular Degeneration Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Gene Therapy for Age-related Macular Degeneration Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Gene Therapy for Age-related Macular Degeneration Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Gene Therapy for Age-related Macular Degeneration Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Gene Therapy for Age-related Macular Degeneration Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2024-2029
Table 30. RetroSense Therapeutics Company Summary
Table 31. RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Product Offerings
Table 32. RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Revenue (US$, Mn) & (2018-2023)
Table 33. RetroSense Therapeutics Key News & Latest Developments
Table 34. REGENXBIO Company Summary
Table 35. REGENXBIO Gene Therapy for Age-related Macular Degeneration Product Offerings
Table 36. REGENXBIO Gene Therapy for Age-related Macular Degeneration Revenue (US$, Mn) & (2018-2023)
Table 37. REGENXBIO Key News & Latest Developments
Table 38. AGTC Company Summary
Table 39. AGTC Gene Therapy for Age-related Macular Degeneration Product Offerings
Table 40. AGTC Gene Therapy for Age-related Macular Degeneration Revenue (US$, Mn) & (2018-2023)
Table 41. AGTC Key News & Latest Developments
List of Figures
Figure 1. Gene Therapy for Age-related Macular Degeneration Segment by Type in 2022
Figure 2. Gene Therapy for Age-related Macular Degeneration Segment by Application in 2022
Figure 3. Global Gene Therapy for Age-related Macular Degeneration Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Gene Therapy for Age-related Macular Degeneration Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Gene Therapy for Age-related Macular Degeneration Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Gene Therapy for Age-related Macular Degeneration Revenue in 2022
Figure 8. By Type - Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share, 2018-2029
Figure 9. By Application - Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share, 2018-2029
Figure 10. By Type - Global Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share, 2018-2029
Figure 12. By Application - Global Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share, 2018-2029
Figure 14. By Region - Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share, 2018-2029
Figure 15. By Country - North America Gene Therapy for Age-related Macular Degeneration Revenue Market Share, 2018-2029
Figure 16. US Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Gene Therapy for Age-related Macular Degeneration Revenue Market Share, 2018-2029
Figure 20. Germany Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 21. France Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Gene Therapy for Age-related Macular Degeneration Revenue Market Share, 2018-2029
Figure 28. China Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 32. India Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Gene Therapy for Age-related Macular Degeneration Revenue Market Share, 2018-2029
Figure 34. Brazil Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Gene Therapy for Age-related Macular Degeneration Revenue Market Share, 2018-2029
Figure 37. Turkey Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Gene Therapy for Age-related Macular Degeneration Revenue, (US$, Mn), 2018-2029
Figure 41. RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. REGENXBIO Gene Therapy for Age-related Macular Degeneration Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. AGTC Gene Therapy for Age-related Macular Degeneration Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
